Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

NCT02436668 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

430

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Adenocarcinoma

Interventions

DRUG: Ibrutinib
DRUG: Gemcitabine
DRUG: Nab-paclitaxel

Sponsor

Pharmacyclics LLC.